Asset
DAROVASERTIB
IDEAYA Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05987332 | phase2_3 | active_not_recruiting | 2023-10-31 | 2027-01-15 | IDEAYA Biosciences | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma |
| NCT03947385 | phase1_2 | recruiting | 2019-06-28 | 2027-01-29 | IDEAYA Biosciences | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions |
FDA applications (0)
This company has no applications containing this asset.